New Oncology Closes Financing Round
News Mar 19, 2015
New Oncology has announced the completion of a financing round to prepare the market launch of NEOliquid, a non-invasive blood test that identifies therapeutically actionable genome alterations in the circulating free tumour DNA (ctDNA) of cancer patients.
NEOliquid allows detection not only of mutations, but also of therapeutically relevant gene fusions (e.g. affecting ALK, ROS or RET kinases) with the highest sensitivity and confidence. Existing shareholders as well as additional investors participated in this financing round. Financial details were not disclosed.
“We are excited about the prospect of identifying therapeutically relevant genome alterations without the need to perform painful biopsies. This financing round is a critical step towards this important goal." commented Prof. Roman Thomas, founder of New Oncology.
Single Blood Test 'CancerSEEK' Screens for Eight Cancer TypesNews
Johns Hopkins Kimmel Cancer Center researchers developed a single blood test that screens for eight common cancer types and helps identify the location of the cancer.READ MORE